Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 205-213

  Gast, Marie Christine W ^a   van Gils, Carla H ^b   Wessels, Lodewijk F A ^c,d   Harris, Nathan ^e   Bonfrer, Johannes M G ^f   Rutgers, Emiel J T H ^f   Schellens, Jan H M ^c,g   Beijnen, Jos H ^a,g  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^e CIPHERGEN BIOSYSTEMS INC   (United States)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Breast cancer; Diagnosis; Protein profiling; Serum; Surface enhanced laser desorption ionisation time of flight mass spectrometry

Indexed keywords

BIOCHEMICAL MARKER; COMPLEMENT COMPONENT C3A; FIBRINOGEN; INTER ALPHA TRYPSIN INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION STUDY;

ADULT; AGE FACTORS; AGED; BLOOD PROTEINS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; COMPLEMENT C3A; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GLYCOPROTEINS; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 68249152615     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000426     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al: SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/ - based on November 2007 SEER data submission, posted on the SEER website, 2008.
3. Stieber P, Molina R, Chan DW, et al: Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin Lab 49: 15-24, 2003.
4. Banks RE, Dunn MJ, Hochstrasser DF, et al: Proteomics: new perspectives, new biomedical opportunities. Lancet 356: 1749-1756, 2000.
5. Becker S, Cazares LH, Watson P, et al: Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 11: 907-914, 2004.
6. Belluco C, Petricoin EF, Mammano E, et al: Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in Stage 1 breast cancer. Ann Surg Oncol 14: 2470-2476, 2007.
7. Hu Y, Zhang S, Yu J, et al: SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 14: 250-255, 2005.
8. Laronga C, Becker S, Watson P, et al: SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 19: 229-238, 2003.
9. Li J, Zhang Z, Rosenzweig J, et al: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304, 2002.
10. Li J, Orlandi R, White CN, et al: Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51: 2229-2235, 2005.
11. Mathelin C, Cromer A, Wendling C, et al: Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 96: 83-90, 2006.
12. Vlahou A, Laronga C, Wilson L, et al: A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 4: 203-209, 2003.
13. Goncalves A, Esterni B, Bertucci F, et al: Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25: 981-989, 2006.
14. Pusztai L, Gregory BW, Baggerly KA, et al: Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814-1822, 2004.
15. Heike Y, Hosokawa M, Osumi S, et al: Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res 25: 1197-1203, 2005.
16. Ransohoff DF: Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97: 315-319, 2005.
17. Villanueva J, Philip J, Chaparro CA, et al: Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4: 1060-1072, 2005.
18. Gast MC, Bonfrer JM, van Dulken EJ, et al: SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. Cancer Biomark 2: 235-248, 2006.
19. Hu J, Coombes KR, Morris JS, et al: The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 3: 322-331, 2005.
20. Karsan A, Eigl BJ, Flibotte S, et al: Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 51: 1525-1528, 2005.
21. van Winden AWJ, Gast MCW, Beijnen JH, et al: Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics 2: 4, 2009.
22. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
23. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
24. Bertucci F, Birnbaum D and Goncalves A: Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 5: 1772-1786, 2006.
25. Hugli TE: Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem 250: 8293-8301, 1975.
26. Bohana-Kashtan O, Ziporen L, Donin N, et al: Cell signals transduced by complement. Mol Immunol 41: 583-597, 2004.
27. Sahu A, Sunyer JO, Moore WT, et al: Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunol Res 17: 109-121, 1998.
28. de Bruijn MH and Fey GH: Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 82: 708-712, 1985.
29. Nettesheim DG, Edalji RP, Mollison KW, et al: Secondary structure of complement component C3a anaphylatoxin in solution as determined by NMR spectroscopy: differences between crystal and solution conformations. Proc Natl Acad Sci USA 85: 5036-5040, 1988.
30. Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999.
31. Carli M, Bucolo C, Pannunzio MT, et al: Fluctuation of serum complement levels in children with neuroblastoma. Cancer 43: 2399-2404, 1979.
32. Gminski J, Mykala-Ciesla J, Machalski M, et al: Immunoglobulins and complement components levels in patients with lung cancer. Rom J Intern Med 30: 39-44, 1992.
33. Maness PF and Orengo A: Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 34: 87-89, 1977.
34. Lee IN, Chen CH, Sheu JC, et al: Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6: 2865-2873, 2006.
35. Habermann JK, Roblick UJ, Luke BT, et al: Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131: 1020-1029, 2006.
36. Ward DG, Suggett N, Cheng Y, et al: Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94: 1898-1905, 2006.
37. Miguet L, Bogumil R, Decloquement P, et al: Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J Proteome Res 5: 2258-2269, 2006.
38. Shin S, Cazares L, Schneider H, et al: Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg 204: 1065-1071, 2007.
39. Han KQ, Huang G, Gao CF, et al: Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 31: 133-139, 2008.
40. Hamad OA, Ekdahl K, Lambris JD and Nilsson B: Complement activation triggered by thrombin receptor-activated platelets. Mol Immunol 44: 180, 2007.
41. Banks RE, Stanley AJ, Cairns DA, et al: Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51: 1637-1649, 2005.
42. Song J, Patel M, Rosenzweig CN, et al: Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 52: 1045-1053, 2006.
43. Fung ET, Yip TT, Lomas L, et al: Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115: 783-789, 2005.
44. Villanueva J, Shaffer DR, Philip J, et al: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284, 2006.
45. Timms JF, Arslan-Low E, Gentry-Maharaj A, et al: Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem 53: 645-656, 2007.
46. Zhou L, Cheng L, Tao L, et al: Detection of hypopharyngeal squamous cell carcinoma using serum proteomics. Acta Otolaryngol 126: 853-860, 2006.
47. Engwegen JY, Helgason HH, Cats A, et al: Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 12: 1536-1544, 2006.
48. Chang SJ, Hou MF, Tsai SM, et al: The association between lipid profiles and breast cancer among Taiwanese women. Clin Chem Lab Med 45: 1219-1223, 2007.
49. Van Lenten BJ, Reddy ST, Navab M, et al: Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol 26: 1687-1688, 2006.
50. Zhang Z, Bast RC Jr, Yu Y, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64: 5882-5890, 2004.
51. Steel LF, Shumpert D, Trotter M, et al: A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3: 601-609, 2003.